Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
June 01, 2023 07:57 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
May 03, 2023 08:26 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
March 02, 2023 08:00 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
February 23, 2023 08:00 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award
February 16, 2023 07:30 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004
January 18, 2023 08:00 ET
|
Pasithea
-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 -- MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...
Majority of Stockholders Support Pasithea Directors at Special Meeting
December 14, 2022 17:18 ET
|
Pasithea
MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group
December 12, 2022 07:00 ET
|
Pasithea
MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
December 06, 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time
November 28, 2022 19:05 ET
|
Pasithea
MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...